Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics director Roy D. Baynes exercised stock options and sold shares in a planned transaction. He exercised options covering 32,750 shares of common stock at exercise prices between $15.43 and $21.38 per share, then sold 32,750 shares in open-market trades at $41.07 and $42.12 per share under a Rule 10b5-1 trading plan adopted on November 17, 2025. After these transactions, he directly owned 37,500 shares of Travere Therapeutics common stock.
Travere Therapeutics SVP and Chief Accounting Officer Sandra Calvin reported an option exercise and share sale. On April 14, 2026, she exercised employee stock options covering 15,250 shares of common stock at exercise prices of $22.40, $8.93, and $20.46 per share. She then sold 21,977 shares of common stock at $41.07 per share in an open-market transaction made under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2025. After these transactions, she directly held 42,353 shares of Travere Therapeutics common stock.
Travere Therapeutics, Inc. chief commercial officer Peter Heerma reported a grant of 14,000 shares of common stock and a related share sale. The 14,000-share award on April 13, 2026 reflects settlement of performance restricted stock units tied to FDA approval of FILSPARI in FSGS. On April 14, 2026, he sold 7,215 shares at an average price of $41.9288 solely to cover tax withholding on the vested units under the company’s equity incentive plan. Following these transactions, he directly holds 138,608 shares of Travere common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported receiving 14,000 shares of common stock as an equity award. The shares were acquired at no cost and are tied to performance restricted stock units granted on January 31, 2025.
According to the disclosure, these PSUs vested on April 13, 2026 after Travere confirmed that the U.S. Food and Drug Administration approved FILSPARI (sparsentan) for FSGS. Following this vesting and share issuance, Rote directly holds 123,087 shares of Travere Therapeutics common stock, reflecting both this award and his existing stake.
Travere Therapeutics, Inc. director and CEO Eric M. Dube reported a PSU vesting and related share sales. On April 13, 2026, he acquired 64,000 shares of common stock at no cost through vested performance restricted stock units, triggered by FDA approval of FILSPARI (sparsentan) in FSGS.
On April 15, 2026, he sold 56,815 shares at a weighted average price of $41.01, 7,165 shares at a weighted average price of $41.75, and 20 shares at $42.66, all in open-market transactions under a Rule 10b5-1 trading plan that also covered tax obligations from the PSU vesting. Following these transactions, he directly holds 432,886 shares of Travere common stock, the same level as before the grant and sales.
Travere Therapeutics, Inc.’s Chief Legal Officer and General Counsel Elizabeth E. Reed exercised employee stock options and sold shares of common stock in a series of transactions. She exercised options to acquire 37,500 shares at exercise prices of $19.08, $17.96, and $15.46 per share and also received 14,000 shares as a grant or award.
Ms. Reed then sold a total of 51,500 shares of common stock in open-market and related transactions at weighted average prices around $41–$43 per share, leaving her with 105,211 shares owned directly after the transactions. Footnotes state that certain sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025 and that part of the sales were mandatory “sell to cover” trades to satisfy tax withholding obligations.
The 14,000-share award reflects performance restricted stock units granted on January 31, 2025 that vested on April 13, 2026 after the U.S. Food and Drug Administration approved FILSPARI (sparsentan) in FSGS.
Travere Therapeutics’ chief financial officer, Christopher R. Cline, reported a mix of equity compensation and share sales in Travere Therapeutics, Inc. common stock. He received 14,000 shares on April 13, 2026 as a grant tied to performance restricted stock units that vested after the U.S. Food and Drug Administration approved FILSPARI (sparsentan) for FSGS.
Between April 13 and 15, 2026, he sold a total of 8,327 shares in open-market transactions at prices ranging from about $28.85 to $42.61. Footnotes explain that part of these sales were mandated “sell to cover” transactions to satisfy tax withholding on vested restricted and performance stock units, and others were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. After these transactions, he directly holds 116,899 shares of Travere common stock.
Travere Therapeutics’ chief medical officer Jula Inrig reported a mix of equity award vesting and routine share sales. On April 13, 2026, 14,000 shares of common stock were acquired at no cost upon the vesting of performance restricted stock units tied to FDA approval of FILSPARI (sparsentan) in FSGS.
On April 14, 2026, Inrig sold 7,215 shares of common stock at an average price of $41.9288 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. On April 15, 2026, a further 1,018 shares were sold at $42.61 per share to cover tax withholding obligations related to the PSU settlement, as required by the company’s equity incentive plans. Following these transactions, Inrig held 111,473 shares of Travere Therapeutics common stock directly.
Travere Therapeutics, Inc. (TVTX) officer Eric M. Dube reported a proposed sale of 64,000 common shares, with an aggregate market value of $2,629,832.99, approximately April 15, 2026. The shares were acquired from the issuer through restricted-stock vesting on April 13, 2026, as compensation; the reported Rule 10b5-1 plan adoption date is June 16, 2025. Five earlier sales by Dube are also listed, from January 23 through April 1, 2026, with amounts of 8,135, 51,865, 100,087, 60,000, and 60,000 shares.
Travere Therapeutics, Inc. (TVTX) officer Elizabeth Reed reported a proposed sale of 6,785 common shares, with an approximate sale date of April 15, 2026 and an aggregate market value of $283,823.34. Reed acquired the shares from the issuer as performance shares on April 13, 2026. The reported plan-adoption or instruction date, if relying on Rule 10b5-1, is June 16, 2025.